BRPI1014867A2 - anticorpos contra a tweak humana e usos dos mesmos. - Google Patents

anticorpos contra a tweak humana e usos dos mesmos.

Info

Publication number
BRPI1014867A2
BRPI1014867A2 BRPI1014867A BRPI1014867A BRPI1014867A2 BR PI1014867 A2 BRPI1014867 A2 BR PI1014867A2 BR PI1014867 A BRPI1014867 A BR PI1014867A BR PI1014867 A BRPI1014867 A BR PI1014867A BR PI1014867 A2 BRPI1014867 A2 BR PI1014867A2
Authority
BR
Brazil
Prior art keywords
antibodies against
against human
human tweak
tweak
antibodies
Prior art date
Application number
BRPI1014867A
Other languages
English (en)
Inventor
Hendrik Knoetgen
Jens Niewoehner
Monika Baehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1014867A2 publication Critical patent/BRPI1014867A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1014867A 2009-04-02 2010-03-30 anticorpos contra a tweak humana e usos dos mesmos. BRPI1014867A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02
PCT/EP2010/002009 WO2010115555A2 (en) 2009-04-02 2010-03-30 Antibodies against human tweak and uses thereof

Publications (1)

Publication Number Publication Date
BRPI1014867A2 true BRPI1014867A2 (pt) 2016-04-12

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014867A BRPI1014867A2 (pt) 2009-04-02 2010-03-30 anticorpos contra a tweak humana e usos dos mesmos.

Country Status (23)

Country Link
US (3) US8093006B2 (pt)
EP (2) EP2414398A2 (pt)
JP (1) JP5596777B2 (pt)
KR (1) KR101344611B1 (pt)
CN (1) CN102369219A (pt)
AR (1) AR076020A1 (pt)
AU (1) AU2010233997A1 (pt)
BR (1) BRPI1014867A2 (pt)
CA (1) CA2756245A1 (pt)
CL (1) CL2011002452A1 (pt)
CO (1) CO6362025A2 (pt)
CR (1) CR20110462A (pt)
EC (1) ECSP11011362A (pt)
IL (1) IL214355A0 (pt)
MA (1) MA33097B1 (pt)
MX (1) MX2011010117A (pt)
NZ (1) NZ594347A (pt)
PE (1) PE20120577A1 (pt)
RU (1) RU2011143903A (pt)
SG (2) SG10201404107SA (pt)
TW (1) TWI423815B (pt)
UA (1) UA105520C2 (pt)
WO (1) WO2010115555A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
PE20131411A1 (es) 2010-10-05 2013-12-16 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
EP2683740B1 (en) 2011-03-10 2018-07-04 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
IL282650B2 (en) * 2018-10-31 2024-09-01 Astellas Pharma Inc Anti-human fn14 antibody
WO2025005938A1 (en) * 2023-06-26 2025-01-02 Memorial Sloan-Kettering Cancer Center Antibodies and antigen binding fragments thereof binding to chimeric receptors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
CN101024831A (zh) 1996-08-07 2007-08-29 拜奥根Idec马萨诸塞公司 肿瘤坏死因子相关配基
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
WO1998035061A2 (en) 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP1021542B1 (en) 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
EE200100372A (et) * 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
AU2937300A (en) 1999-03-04 2000-09-21 Vision Sciences, Inc. Image sensor's unit cell with individually controllable electronic shutter circuit
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
WO2001030374A1 (en) 1999-10-22 2001-05-03 The University Of Pittsburgh Stem cell engraftment-enhancing cellular proteins and their uses
AU8028400A (en) 1999-10-22 2001-05-08 Scimed Life Systems, Inc. Guided injection device
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CA2887716C (en) 2002-04-09 2017-01-24 Biogen Idec Ma Inc. Methods for treating tweak-related conditions
WO2006052926A2 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
US20090068102A1 (en) 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
BRPI0608012A2 (pt) 2005-03-07 2009-11-03 Genentech Inc método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
MA33097B1 (fr) 2012-03-01
US20120207750A1 (en) 2012-08-16
WO2010115555A3 (en) 2011-01-06
MX2011010117A (es) 2011-10-14
KR101344611B1 (ko) 2013-12-30
US8883976B2 (en) 2014-11-11
CO6362025A2 (es) 2012-01-20
UA105520C2 (uk) 2014-05-26
JP2012521771A (ja) 2012-09-20
CA2756245A1 (en) 2010-10-14
AU2010233997A1 (en) 2011-08-18
NZ594347A (en) 2012-09-28
IL214355A0 (en) 2011-09-27
CL2011002452A1 (es) 2012-03-23
CR20110462A (es) 2011-09-21
WO2010115555A2 (en) 2010-10-14
TW201039847A (en) 2010-11-16
US20100255008A1 (en) 2010-10-07
PE20120577A1 (es) 2012-05-23
EP2597104A1 (en) 2013-05-29
SG175005A1 (en) 2011-11-28
AR076020A1 (es) 2011-05-11
US8852887B2 (en) 2014-10-07
US8093006B2 (en) 2012-01-10
RU2011143903A (ru) 2013-05-10
US20120083015A1 (en) 2012-04-05
SG10201404107SA (en) 2014-10-30
KR20110122868A (ko) 2011-11-11
TWI423815B (zh) 2014-01-21
ECSP11011362A (es) 2011-10-31
JP5596777B2 (ja) 2014-09-24
CN102369219A (zh) 2012-03-07
EP2414398A2 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
BRPI1014867A2 (pt) anticorpos contra a tweak humana e usos dos mesmos.
SI2358756T2 (sl) Visokoafinitetna humana protitelesa proti PCSK9
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
IL261257B (en) Humanized fc㚚šššššr mice
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI0919531A2 (pt) anticorpos contra il17 humana e usos dos mesmos
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
BRPI1008709A2 (pt) composições e usos das mesmas.
DK2582728T3 (da) Humane antistof-lægemiddelkonjugater mod vævsfaktor
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
BRPI1011710A2 (pt) lágrimas artificiais e usos trapêuticos
DK2475294T3 (da) Implanterbar sensor
BR112012003780A2 (pt) pregão semântico
BRPI1010644A2 (pt) inibidores da replicação do vírus da imunodeficiência humana
BRPI0924512A2 (pt) método e aparelho de fornecimento de execução de aplicativos seguros
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
EP2207803A4 (en) Cd9-specific human antibodies
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
BRPI1007811A2 (pt) nacela de turborreator, e, turborreator
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
FI20096339L (fi) Liima-aine, menetelmä sen valmistamiseksi sekä sen käyttö
HRP20181973T1 (hr) Poboljšana anti humana fraktalkinska protutijela i njihova uporaba
BR112013002544A2 (pt) seção de armario e armario

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]